配对原发与转移性甲状腺乳头状癌的全外显子组测序
对14对匹配的远处转移灶、原发甲状腺乳头状癌(PTC)肿瘤及正常组织进行全外显子组测序,分析点突变、拷贝数改变、癌细胞分数和突变特征。结果显示原发灶与转移灶基因组存在差异,转移灶中位62%的体细胞突变在原发肿瘤中未检测到,且DNA甲基化与转录抑制相关基因变异限于转移灶。
要点
- 原发与转移性PTC存在基因组差异,转移灶中位62%体细胞突变原发灶缺失。
- BRAF、NRAS、HRAS等驱动基因突变在原发和转移灶共享且倾向克隆性。
- SIN3A、RBBP1、CHD4等DNA甲基化与转录抑制基因变异限于转移灶。
核心结论
- 原发PTC与远处转移灶的体细胞变异谱不同,转移灶基因组分析可识别原发灶未检测到的潜在临床相关信息。
研究设计与样本
- 对14例匹配的远处转移灶、原发PTC肿瘤和正常组织进行全外显子组测序,并采用先进生物信息学方法定义点突变、拷贝数改变、癌细胞分数和突变特征。
主要发现
- 转移灶中位62%(范围21-92%)的体细胞突变在原发肿瘤中未检测到。
- BRAF、NRAS和HRAS等已知驱动基因突变在原发和转移灶共享且倾向克隆性。
- SIN3A、RBBP1和CHD4等DNA甲基化与转录抑制信号基因的可能有害变异限于转移灶。
- 转移灶与原发灶特异性或富集突变之间观察到突变特征偏移。
临床怎么用
- 对PTC远处转移患者,转移灶基因组分析可能识别原发灶未检测到的信息,或影响个体化治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Distant metastasis is a rare occurrence in thyroid cancer, and it can be associated with poor prognosis. The genomic repertoires of various solid malignancies have previously been reported but remain underexplored in metastatic papillary thyroid cancer (PTC). Furthermore, whether distant metastases harbor distinct genetic alterations beyond those observed in primary tumors is unknown. Methods: We performed whole-exome sequencing on 14 matched distant metastases, primary PTC tumors, and normal tissues. Point mutations, copy number alterations, cancer cell fractions, and mutational signatures were defined using the state-of-the-art bioinformatics methods. All likely deleterious variants were validated by orthogonal methods. Results: Genomic differences were observed between primary and distant metastatic deposits, with a median of 62% (range 21-92%) of somatic mutations detected in metastatic tissues, but absent from the corresponding primary tumor sample. Mutations in known driver genes including BRAF, NRAS, and HRAS were shared and preferentially clonal in both sites. However, likely deleterious variants affecting DNA methylation and transcriptional repression signaling genes including SIN3A, RBBP1, and CHD4 were found to be restricted in the metastatic lesions. Moreover, a mutational signature shift was observed between the mutations that are specific or enriched in the metastatic and primary lesions. Conclusions: Primary PTC and distant metastases differ in their range of somatic alterations. Genomic analysis of distant metastases provides an opportunity to identify potentially clinically informative alterations not detected in primary tumors, which might influence decisions for personalized therapy in PTC patients with distant metastasis.
引用
- Masoodi T, Siraj AK, Siraj S, et al. Whole-Exome Sequencing of Matched Primary and Metastatic Papillary Thyroid Cancer. Thyroid. 2019. PMID: 31668133. doi:10.1089/thy.2019.0052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。